Precision comparison of bone scan and [18]FDG PET/CT for bone staging in patients with high-risk prostate cancer at biopsy

#### Samuel Otis-Chapados PGY-3 CHU de Québec

Gabriel Dubois, Michelle Bergeron, Étienne Lavallée, Thierry Dujardin, Rabi Tiguert, Louis Lacombe, Michele Lodde, Paul-Jeremy Toren, Yves Fradet, François-Alexandre Buteau, Frédéric Pouliot, M.D. Ph.D. F.R.C.S.C.



### Disclosure

None



### Introduction

- Accuracy of [18] FDG PET/CT for prostate cancer staging is limited.
- Detection rates for metastasis were similar between <sup>18</sup>F-choline and <sup>18</sup>F-FDG PET-CT in recurrent and metastatic PCa.
- FDG-PET captation is a poor prognostic marker in metastatic PCa

Beauregard, 2010


Jadvar 2015, Mireilles 2010, Jadvar, 2013



# Introduction

- Gleason 8-10 cancer at biopsy
  - FDG-PET/CT+BS
  - Radical prostatectomy
- High intraprostatic FDG uptake (SUVmax) was predictive of
  - Adverse pathological prognostic factors
  - Early biochemical recurrence
  - Shorter time to castration resistance

#### <sup>18</sup>FDG-PET/CT





## **Objectives**

- 1. Compare the diagnostic accuracies between FDG-PET/CT and bone scintigraphy at primary staging of patients with Gleason  $\geq$  8 PCa at biopsy;
- 2. Determine if FDG-PET/CT alone can be used as a staging procedure in these patients.



## Methods

- Between 2010 & 2016
  - 261 PCa patients with Gleason  $\ge$  8 at biopsy
  - Staging with bone scan + FDG PET/CT
- Imaging analysis
  - True positive for metastatic status:
    - Concordant findings between both imaging modalities
    - Discordant findings between imaging modalities=reference standard definition for true positive
      - biopsy
      - follow-up imaging showing progression
      - concordance with a third imaging technique

#### - False positive

• patients underwent curative treatment with complete biochemical response



#### Patients and tumor characteristics

Number of patients (all, n))	261		
Patients with bone metastasis (n)	33		
Average age (years±SD)	$66 \pm 8,3$		
Chronology between bone scan & FDG-PET/CT Average (days±SD) Median % pt with bone scan done before FDG-PET/CT % FDG-PET/CT done before Bone scan	$23 \pm 50,5$ 12 78 22		
PSA (ng/mL) No metastasis Mono metastasis Oligo metastasis (<5 metastasis) Pluri metastasis	7,6 15,7 29,0 84,0		
Median Gleason sum at biopsy No metastasis Mono metastasis Oligo metastasis Pluri metastasis	8 8 9 9		




# FDG-PET/CT and bone scan accuracies in mono, oligo and plurimetastasis patients

	Bone scan	FDG-PET/CT	Total	
Patients with bone metastasis	26 (78,8%)	33 (100%)	33	
Plurimetastasis	16 (100%)	16 (100%)	16	FDG PET/CT
Oligo metastasis	6 (66,7%)	9 (100%)	9	detect 21% more bone
Mono metastasis	4 (50,0%)	8 (100%)	8	mets
False positive	5 (2,2%)	3 (1,3%)	227	


UNIVERSITÉ

# % missed metastatic patients by bone scan in mono, oligo and pluri metastasis






#### Radiologic comparison between bone scan & FDG-PET/CT



#### Radiologic comparison between bone scan & FDG-PET/CT



Left



#### Sensibility and Specificity in Bone scan and FDG-PET/CT

	Bone Scan	FDG-PET/CT
Sensibility (%)	78,8	100,0
Specificity (%)	97,8	98,7
PPV (%)	83,9	91,7
NPV (%)	97,0	100,0



Comparision of patients with bone scan + or – when FDG PET/CT is +

	Patients	PSA (median)	Gleason (median)	Median time elapsed between Bone scan & FDG PET/CT (days)		
FDG PET/CT + & Bone scan -	7	20,7	9		34	
FDG PET/CT + & Bone scan +	26	68,5	9		24	



# Limitations

- Retrospective study
- Time and chronology between FDG PET-CT and bone scan may have impacted results?
- Single reader, no interobserver validation
- Unblinded to the other imaging
- Reference truth standard was correlation b/w modalities



### Conclusions

- For patients with Gleason ≥ 8 prostate cancers at biopsy, FDG PET/CT can be used to help clinical decision :
  - at least as accurate and maybe superior to bone scintigraphy for bone metastasis detection
    - detects <u>21%</u> more patients with bone metastasis than bone scan
  - FDG uptake in the prostate is associated with:
    - shorter time to biochemial failure after RP
    - LN positivity
    - shorter time to castration resistance

